Literature DB >> 11369030

Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture.

M Ibi1, H Sawada, M Nakanishi, T Kume, H Katsuki, S Kaneko, S Shimohama, A Akaike.   

Abstract

This study was undertaken to determine whether 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25-(OH)(2)D(3)], an active metabolite of vitamin D, protects dopaminergic neurons against the neurotoxic effects of glutamate and dopaminergic toxins using rat mesecephalic culture. Brief glutamate exposure elicited cytotoxicity in both dopaminergic and non-dopaminergic neurons. Pretreatment, but not co-administration, of 1 alpha,25-(OH)(2)D(3) protected both types of neurons against the cytotoxicity of glutamate in a concentration- and time-dependent manner. The neuroprotective effect of 1 alpha,25-(OH)(2)D(3) was inhibited by the protein synthesis inhibitor, cycloheximide. To investigate the mechanisms of these neuroprotective effects, we examined the effects of 1 alpha,25-(OH)(2)D(3) on neurotoxicity induced by calcium ionophore and reactive oxygen species (ROS). Pretreatment with 1 alpha,25-(OH)(2)D(3) protected both types of neurons against the cytotoxicity induced by A23187 in a concentration-dependent manner. Furthermore, 24-h pretreatment with 1 alpha,25-(OH)(2)D(3) concentration-dependently protected both types of neurons from ROS-induced cytotoxicity. A 24-h incubation with 1 alpha,25-(OH)(2)D(3) inhibited the increase in intracellular ROS level following H(2)O(2) exposure. A 24-h exposure to 1-methyl-4-phenylpyridium ion (MPP(+)) or 6-hydroxydopamine (6-OHDA) exerted selective neurotoxicity on dopaminergic neurons, and these neurotoxic effects were ameliorated by 1 alpha,25-(OH)(2)D(3). These results suggest that 1 alpha,25-(OH)(2)D(3) provides protection of dopaminergic neurons against cytotoxicity induced by glutamate and dopaminergic toxins by facilitating cellular functions that reduce oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369030     DOI: 10.1016/s0028-3908(01)00009-0

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  66 in total

1.  Vitamin D deficiency exacerbates experimental stroke injury and dysregulates ischemia-induced inflammation in adult rats.

Authors:  Robyn Balden; Amutha Selvamani; Farida Sohrabji
Journal:  Endocrinology       Date:  2012-03-09       Impact factor: 4.736

2.  Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine.

Authors:  Michael P Smith; Anita Fletcher-Turner; David M Yurek; Wayne A Cass
Journal:  Neurochem Res       Date:  2006-04       Impact factor: 3.996

3.  Calcitriol promotes augmented dopamine release in the lesioned striatum of 6-hydroxydopamine treated rats.

Authors:  Wayne A Cass; Laura E Peters; Anita M Fletcher; David M Yurek
Journal:  Neurochem Res       Date:  2014-05-25       Impact factor: 3.996

4.  Vitamin D supplementation: a useful strategy for restless legs syndrome exacerbation in a patient with Turner syndrome.

Authors:  Laura Buratti; Maria Paola Luconi; Giovanna Viticchi; Leandro Provinciali; Mauro Silvestrini
Journal:  Neurol Sci       Date:  2017-03-01       Impact factor: 3.307

5.  Nutrient biomarkers and vascular risk factors in subtypes of mild cognitive impairment: a cross-sectional study.

Authors:  Y Yin; Y Fan; F Lin; Y Xu; J Zhang
Journal:  J Nutr Health Aging       Date:  2015-01       Impact factor: 4.075

6.  Effects of cholecalciferol on behavior and production of reactive oxygen species in female mice subjected to corticosterone-induced model of depression.

Authors:  Suene Vanessa da Silva Souza; Priscila Batista da Rosa; Vivian Binder Neis; Júlia Dubois Moreira; Ana Lúcia S Rodrigues; Morgana Moretti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-28       Impact factor: 3.000

7.  Efficacy of vitamin D replacement therapy in restless legs syndrome: a randomized control trial.

Authors:  Siraj Omar Wali; Bahaa Abaalkhail; Faris Alhejaili; S R Pandi-Perumal
Journal:  Sleep Breath       Date:  2018-11-14       Impact factor: 2.816

8.  Serum 25-hydroxyvitamin D concentration and cognitive impairment.

Authors:  David J Llewellyn; Kenneth M Langa; Iain A Lang
Journal:  J Geriatr Psychiatry Neurol       Date:  2008-12-10       Impact factor: 2.680

Review 9.  Fall prevention and vitamin D in the elderly: an overview of the key role of the non-bone effects.

Authors:  Cedric Annweiler; Manuel Montero-Odasso; Anne M Schott; Gilles Berrut; Bruno Fantino; Olivier Beauchet
Journal:  J Neuroeng Rehabil       Date:  2010-10-11       Impact factor: 4.262

10.  Low 25-hydroxyvitamin D levels and cognitive impairment in hemodialysis patients.

Authors:  Kamran Shaffi; Hocine Tighiouart; Tammy Scott; Kristina Lou; David Drew; Daniel Weiner; Mark Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.